LQDA Graph | LIQUIDIA CORPORATION

LQDA Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

2026-06-30: Revenue $171.68M; Cost of revenue (m); Research and development $17.18M; Selling, general and administrative $57.43M.
2026-03-31: Revenue $132.87M; Cost of revenue (m); Research and development $12.57M; Selling, general and administrative $46.94M.
2025-12-31: Revenue $92.02M*; Cost of revenue (m); Research and development $16.94M*; Selling, general and administrative $48.24M*.
2025-09-30: Revenue $54.34M; Cost of revenue (m); Research and development $9.35M; Selling, general and administrative $40.06M.

Product or service

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

Segment

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period end	Revenue	Cost of revenue	Research and development	Selling, general and administrative	Income tax	Net income
2026-06-30	$171.68M	(m)	$17.18M	$57.43M	$6.97M	$74.72M
2026-03-31	$132.87M	(m)	$12.57M	$46.94M	$3.92M	$52.86M
2025-12-31	$92.02M*	(m)	$16.94M*	$48.24M*	(m)	$14.55M*
2025-09-30	$54.34M	(m)	$9.35M	$40.06M	(m)	-$3.53M
2025-06-30	$8.84M	(m)	$6.02M	$38.82M	$0.00	-$41.58M
2025-03-31	$3.12M	$1.52M	$6.97M	$30.06M	$0.00	-$38.37M
2024-12-31	$2.92M	(m)	(m)	(m)	(m)	-$38.51M
2024-09-30	$4.45M	$1.56M	$11.89M	$20.18M	(m)	-$31.03M
2024-06-30	$3.66M	$1.49M	$9.42M	$19.94M	(m)	-$28.67M
2024-03-31	$2.97M	$1.47M	$10.06M	(m)	(m)	-$30.08M
2023-12-31	$4.53M	(m)	(m)	(m)	(m)	-$27.45M
2023-09-30	$3.68M	$570.00K	$7.44M	(m)	(m)	-$15.79M
2023-06-30	$4.79M	$671.00K	$17.70M	(m)	(m)	-$23.52M
2023-03-31	$4.49M	$654.00K	$5.28M	(m)	(m)	-$11.74M
2022-09-30	$3.17M	$740.00K	$4.51M	(m)	(m)	-$9.09M
2022-06-30	$3.92M	$731.00K	$5.22M	(m)	(m)	-$9.45M
2022-03-31	$3.49M	$694.00K	$4.73M	(m)	$0.00	-$15.94M
2021-09-30	$3.18M	$890.00K	$4.49M	(m)	$0.00	-$7.28M
2021-06-30	$3.38M	$714.00K	$4.59M	(m)	$0.00	-$6.55M
2021-03-31	$3.08M	$694.00K	$6.05M	(m)	$0.00	-$9.18M
2020-09-30	$0.00	$0.00	$7.66M	(m)	(m)	-$14.97M
2020-06-30	$0.00	$0.00	$8.49M	(m)	$0.00	-$13.92M
2020-03-31	$0.00	$0.00	$10.82M	(m)	$0.00	-$14.79M

Revenue and expense 6 month

Period end	Revenue	Cost of revenue	Research and development	Selling, general and administrative	Income tax	Net income
2026-06-30	$304.54M	(m)	$29.75M	$104.37M	$10.89M	$127.58M
2025-06-30	$11.96M	(m)	$12.99M	$68.89M	$0.00	-$79.95M
2024-06-30	$6.63M	$2.96M	$19.48M	$40.19M	(m)	-$58.75M
2023-06-30	$9.28M	$1.32M	$22.97M	(m)	(m)	-$35.26M
2022-06-30	$7.41M	$1.43M	$9.95M	(m)	(m)	-$25.39M
2021-06-30	$6.46M	$1.41M	$10.65M	(m)	$0.00	-$15.73M
2020-06-30	$0.00	$0.00	$19.31M	(m)	$0.00	-$28.71M

Revenue and expense 9 month

Period end	Revenue	Cost of revenue	Research and development	Selling, general and administrative	Income tax	Net income
2025-09-30	$66.30M	(m)	$22.33M	$108.94M	(m)	-$83.48M
2024-09-30	$11.08M	$4.53M	$31.37M	$60.37M	(m)	-$89.78M
2023-09-30	$12.96M	$1.90M	$30.41M	(m)	(m)	-$51.05M
2022-09-30	$10.57M	$2.17M	$14.46M	(m)	(m)	-$34.48M
2021-09-30	$9.64M	$2.30M	$15.14M	(m)	$0.00	-$23.02M
2020-09-30	$0.00	$0.00	$26.97M	(m)	(m)	-$43.68M

Revenue and expense 12 month

Period end	Revenue	Cost of revenue	Research and development	Selling, general and administrative	Income tax	Net income
2025-12-31	$158.32M	(m)	$39.28M	$157.18M	$0.00	-$68.92M
2024-12-31	$14.00M	$5.88M	$47.84M	$81.57M	$0.00	-$130.39M
2023-12-31	$17.49M	$2.89M	$43.24M	$44.74M	$0.00	-$78.50M
2022-12-31	$15.94M	$2.86M	$19.43M	(m)	$0.00	-$41.02M
2021-12-31	$12.85M	$3.02M	$20.52M	(m)	$0.00	-$34.58M
2020-12-31	$739.63K	$237.71K	$32.22M	(m)	$0.00	-$59.76M
2019-12-31	$8.07M	(m)	$40.49M	(m)	$0.00	-$47.58M

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Amneal Pharmaceuticals, Inc. (AMRX)		$6.326B	25.62
RHYTHM PHARMACEUTICALS, INC. (RYTM)	United States	$6.771B	-37.20
Alkermes plc. (ALKS)		$6.844B	132.74
Mirum Pharmaceuticals, Inc. (MIRM)	United States	$5.798B	-8.81
Travere Therapeutics, Inc. (TVTX)	United States	$5.712B	-123.10
Oruka Therapeutics, Inc. (ORKA)	United States	$5.663B	-43.76
Cogent Biosciences, Inc. (COGT)	United States	$5.450B	-17.61
IONIS PHARMACEUTICALS INC (IONS)	United States	$7.277B	-23.25
Gossamer Bio, Inc. (GOSS)	United States	$5.355B	-0.65
PTC THERAPEUTICS, INC. (PTCT)	United States	$5.199B	-177.07